MERSYNDOL FORTE paracetamol 450 mg / codeine phosphate hemihydrate 30 mg / doxylamine succinate 5 mg tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

mersyndol forte paracetamol 450 mg / codeine phosphate hemihydrate 30 mg / doxylamine succinate 5 mg tablet blister pack

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 450 mg; doxylamine succinate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; magnesium stearate; purified talc; stearic acid; povidone; pregelatinised maize starch; crospovidone - indications as at 9 june 2020: mersyndol forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDCO IBUPROFEN 200 and CODEINE PHOSPHATE 12.8 ibuprofen 200 mg and codeine phosphate hemihydrate 12.8 mg tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

medco ibuprofen 200 and codeine phosphate 12.8 ibuprofen 200 mg and codeine phosphate hemihydrate 12.8 mg tablet blister pack

soul pattinson manufacturing pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for the temporary relief of acute moderate pain and inflammation

Boots Ibuprofen and Codeine 200mg / 12.8 mg film-coated tablets Irlanti - englanti - HPRA (Health Products Regulatory Authority)

boots ibuprofen and codeine 200mg / 12.8 mg film-coated tablets

taw pharma (ireland) ltd - ibuprofen; codeine phosphate hemihydrate - film-coated tablet - 200 mg/12.8 milligram(s) - opioids in combination with non-opioid analgesics; codeine and ibuprofen

Panadeine Caplets Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

panadeine caplets

glaxosmithkline nz limited - codeine phosphate hemihydrate 8mg;  ; paracetamol 500mg (fine);  ;   - tablet - 500mg/8mg - active: codeine phosphate hemihydrate 8mg   paracetamol 500mg (fine)     excipient: carnauba wax hypromellose maize starch methylcellulose opadry blue 03b50817 potassium sorbate povidone purified talc starch stearic acid titanium dioxide triacetin water

ParaCode Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

paracode

actavis new zealand limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine;  ; paracetamol 500mg - tablet - 500mg/8mg - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine   paracetamol 500mg excipient: magnesium stearate maize starch povidone starch - indicated for the temporary relief of pain and discomfort associated with: · headache · migraine headache · backache · toothache/dental surgery · menstrual pain · muscular pain · neuralgia · cold and flu symptoms · sore throat · arthritis

ParaCode Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

paracode

actavis new zealand limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine;  ; paracetamol 500mg - tablet - 500mg/8mg - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine   paracetamol 500mg excipient: magnesium stearate maize starch povidone starch

APO-IBUPROFEN/CODEINE 200/12.8 film-coated tablet, blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

apo-ibuprofen/codeine 200/12.8 film-coated tablet, blister pack

arrotex pharmaceuticals pty ltd - ibuprofen, quantity: 200 mg; codeine phosphate hemihydrate, quantity: 12.8 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years (see also section contraindications and special warnings and precuations for use - paediatric use)

SANDOZ IBUPROFEN PLUS CODEINE film coated tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz ibuprofen plus codeine film coated tablet blister pack

sandoz pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for the temporary relief of acute moderate pain and inflammation in patients over the age of 12 years (see also contraindications and paediatric use)

Panafen Plus Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

panafen plus

haleon new zealand ulc - codeine phosphate hemihydrate 12.8mg;  ; ibuprofen 200mg - film coated tablet - 200mg, 12.8mg - active: codeine phosphate hemihydrate 12.8mg   ibuprofen 200mg excipient: cellactose 80 colloidal silicon dioxide hydrogenated vegetable oil hypromellose macrogol 400 microcrystalline cellulose sodium starch glycolate - panafen plus is indicated for the temporary relief of strong pain and discomfort associated with migraine headache, tension headache, period pain, toothache, cold & flu symptoms, back or muscular pain, arthritis and neuralgia. reduces fever.

AMCAL IBUPROFEN PLUS CODEINE film-coated tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

amcal ibuprofen plus codeine film-coated tablet blister pack

cipla australia pty ltd - ibuprofen, quantity: 200 mg; codeine phosphate hemihydrate, quantity: 12.8 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified water; maize starch; glyceryl behenate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - amcal ibuprofen plus codeine is used for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years.